Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation

Purpose: The objective of this study was to determine locoregional recurren ce (LRR) patterns after mastectomy and doxorubicin-based chemotherapy to de fine subgroups of patients who might benefit from adjuvant irradiation, Patients and Methods: A total of 1,031 patients were treated with mastectom y and doxorubicin-based chemotherapy without irradiation on five prospectiv e trials. Median follow-up time wets 116 months. Rates of isolated and tota l LRR (+/- distant metastasis) were calculated by Kaplan-Meier analysis. Results: The 10-year actuarial rates of isolated LRR were 4%, 10%, 21%, and 22% for patients with zero, one to three, four to nine, or greater than or equal to 10 involved nodes, respectively (P < .0001), Chest wall (68%) and supraclavicular nodes (41%) were the most common sites of LRR. T stage (P < .001), tumor size (P < .001), and greater than or equal to 2-mm extranoda l extension (P < .001) were also predictive of LRR. Separate analysis was p erformed for patients with T1 or T2 primary disease and one to three involv ed nodes (n = 404). Those with fewer than 10 nodes examined were at increas ed risk of LRR compared with those with greater than or equal to 10 nodes e xamined (24% v 11%; P = .02). Patients with tumor size greater than 4.0 cm or extranodal extension greater than or equal to 2 mm experienced rates of isolated LRR in excess of 20%, Each of these factors continued to significa ntly predict for LRR in multivariate analysis by Cox logistic regression. Conclusion: Patients with tumors greater than or equal to 4 cm or at least four involved nodes experience LRR rates in excess of 20% and should be off ered adjuvant irradiation. Additionally, patients with one to three involve d nodes and large tumors, extranodal extension greater than or equal to 2 m m, or inadequate axillary dissections experience high rates of LRR and may benefit from postmastectomy irradiation. J Clin Oncol 18:2817-2827. (C) 200 0 by American Society of Clinical Oncology.